How about consistency assessment? Respect the clinical choice of medical institutions

Source: Cypress blue 2018-4-28 Medical Network April 28 news pharmaceutical enterprises that have passed the consistency evaluation, your basin of cold water is here, please accept it The drug companies require that the drug varieties passing the consistency evaluation shall be purchased and used preferentially by medical institutions, and the local human resources and Social Security Bureau shall respond that the clinical selection of medical institutions shall be respected ▍ how about passing? The response of respecting the clinical choice of medical institutions is undoubtedly a basin of cold water pouring on pharmaceutical enterprises It seems that after the drug passes the consistency evaluation, it is not all right The way for the drug to enter the hospital and the medical insurance must be cut through Recently, Foshan Municipal Bureau of human resources and social security issued the implementation plan for centralized drug procurement in public medical institutions (Draft for comments) for public feedback In this feedback, Foshan Municipal Bureau of human resources and social security did not adopt 12 comments Opinion 12 is proposed by Shenzhen xinlitai to "increase the incentive policy that" medical institutions should give priority to purchasing and clinical selection of drug varieties that pass the consistency evaluation " Finally, Foshan Municipal Bureau of human resources and social security did not adopt it because "clinical selection of medical institutions should be respected" The core product of Shenzhen xinlitai Pharmaceutical Co., Ltd is clopidogrel bisulfate tablets, and the two specifications have passed the consistency evaluation According to relevant data, Sanofi accounted for 59.2%, Shenzhen xinlitai for 30.2% and Lepu Pharmaceutical Co., Ltd for 10.6% of the total sales of clopidogrel bisulfate tablets in 2017 This data well explains the claim of Shenzhen xinlitai The reply from Foshan Municipal Bureau of human resources and social security gives many pharmaceutical enterprises a big reminder Although it has paid a lot of cost to pass the consistency evaluation, it is more likely to be a new start to pass the consistency evaluation On a new level, you are facing even stronger competitors ▍ the State Council advocates favorable results As early as March 2016, in the opinions on the consistency evaluation of quality and efficacy of generic drugs issued by the general office of the State Council, it was clearly proposed that the drug varieties through the consistency evaluation should be properly supported in terms of medical insurance payment, and medical institutions should give priority to purchase and clinical use If there are more than three manufacturers that have passed the consistency evaluation for the same kind of drugs, no more varieties that have failed the consistency evaluation will be selected for centralized purchase of drugs On April 3, 2018, the general office of the State Council issued the opinions on reforming and improving the supply guarantee and use policy of generic drugs, which proposed to be included in the procurement catalogue in time, to promote the alternative use of generic drugs, to give play to the incentive role of basic medical insurance and other policies to encourage pharmaceutical enterprises passing the consistency evaluation Timely included in the procurement catalogue The centralized drug purchase organization shall prepare the purchase catalogue according to the general name of the drug Promote equal competition between generic drugs and original drugs with the same quality and efficacy as the original drugs Promote alternative use of generic drugs The generic drugs that are consistent with the quality and efficacy of the original research drugs shall be included in the catalogue of substitutable drugs with the original research drugs, marked in the instruction manual and label, and relevant information shall be released to the society in time, so as to facilitate the selection and use of medical staff and patients Give full play to the incentive role of basic medical insurance We will accelerate the development of payment standards for medical insurance drugs, and pay for generic drugs and original research drugs with the same quality and efficacy as the original research drugs ▍ many places: give priority to purchase and use At the request of the general office of the State Council, many notices have been issued to encourage medical institutions to purchase and use varieties that pass the consistency evaluation On April 11, Heilongjiang health and Family Planning Commission issued the notice on specific opinions on further reform and improvement of drug production, circulation and use policies, which mentioned that it is necessary to implement the drug clinical priority policy through consistency evaluation For drugs passing the consistency evaluation, medical institutions at all levels should give priority to purchasing and using them in clinical practice On March 6, Shaanxi issued a notice to encourage medical institutions to purchase and use the varieties that passed the consistency evaluation All purchasing consortiums and medical institutions at all levels should include them in the list of interchangeable drugs with the original research drugs and give priority to purchase and use On January 25, Jiangsu stipulated that generic drugs that passed the consistency evaluation in the current round of centralized drug purchase cycle will enjoy the same treatment as the original research drugs, and it is allowed to maintain the existing price of the provincial procurement platform, but the enterprise must promise that the sales price of the product in Jiangsu will not be higher than that in other provinces On the one hand, the more realistic problem is to implement the policies to the purchase and clinical use of drugs in medical institutions Even though generic drugs pass the consistency evaluation, there is still a gap between the brand, quality, promotion and imported drugs Under the current situation, it seems that the market of directly competing for imported drugs is not as big as expected In summary, hospitals do not purchase, clinical use, and favorable policies are just empty words.